Trial
NCT02737072
A Study of LY2510924 and Durvalumab in Participants With Solid Tumors
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Eli Lilly and Company
Collaborators
AstraZeneca
Condition
Solid Tumor
Intervention
LY2510924
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-08-12